Mithra Pharmaceuticals S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MITPF research report →
Companywww.mithra.com
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications.
- CEO
- Christophe Marechal
- IPO
- 2020
- Employees
- 270
- HQ
- Liège, BE
Price Chart
Valuation
- Market Cap
- $1.60B
- P/E
- -0.09
- P/S
- 0.36
- P/B
- -0.14
- EV/EBITDA
- -4.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 14.92%
- Op Margin
- -172.63%
- Net Margin
- -432.08%
- ROE
- 498.80%
- ROIC
- -32.14%
Growth & Income
- Revenue
- $40.16M · -40.06%
- Net Income
- $-173,502,000 · -191.01%
- EPS
- $-2.51 · -105.74%
- Op Income
- $-69,321,000
- FCF YoY
- 97.63%
Performance & Tape
- 52W High
- $23.90
- 52W Low
- $6.75
- 50D MA
- $6.75
- 200D MA
- $6.75
- Beta
- 0.60
- Avg Volume
- 285
Get TickerSpark's AI analysis on MITPF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MITPF Coverage
We haven't published any research on MITPF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MITPF Report →